Shares of Exact Sciences – the company behind the at-home colon-cancer test Cologuard – got a boost recently when the FDA approved (earlier than expected) the use of Cologuard among average-risk individuals aged 45 and older. As the test had previously only been approved for people aged 50 and older, this development significantly increases the potential market for the test – and analysts are updating (and upgrading) their prospects for the company as a result. For more, CLICK HERE.